Skip to main content
OpenTrials
Completed

NCT Number: NCT03378011

UVA1 Phototherapy in Acral Vitiligo

evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acral Vitiligo

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Maha Fathy Elmasry

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with acral vitiligo.
  • Patients more than 12 years old.

Exclusion criteria

  • Patients less than 12 years old.
  • Patients with any other skin diseases or autoimmune diseases.
  • Patients taking medical treatment or phototherapy for vitiligo.

Treatment and study plan

phototherapy

Other

phototherapy either UVA1 or topical PUVA on acral vitiligo

Primary outcomes

  1. effect of medium dose UVA1 phototherapy in treatment of acral vitiligo

    Time frame: 1 year

    effect of medium dose UVA1 phototherapy in treatment of acral vitiligo using point counting and vitiligo area severity index (VASI) score

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Dec 19, 2017
Registry last updated
Dec 19, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.